Literature DB >> 21360196

Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

Moeko Noguchi-Shinohara1, Tsuyoshi Hamaguchi, Ichiro Nozaki, Kenji Sakai, Masahito Yamada.   

Abstract

Total tau protein (t-tau) levels in cerebrospinal fluid (CSF) (CSF-tau) are markedly elevated in patients with Creutzfeldt-Jakob disease (CJD). Some CSF-tau may leak into the blood. We evaluated t-tau levels in serum (serum-tau) as a possible marker for the differential diagnosis of CJD from Alzheimer's disease (AD) and other rapidly progressive dementias (RPD). Serum- and CSF-tau levels were determined in patients with sporadic CJD (n = 12), AD (n = 10) and RPD but no CJD (non-CJD-RPD; n = 9) who showed RPD fulfilling the World Health Organization (WHO) criteria for possible CJD at onset and had a final diagnosis other than CJD. We also analyzed serum-tau levels in healthy volunteers as a control group (n = 10). Serum- as well as CSF-tau levels were significantly elevated in CJD group compared to those in AD, non-CJD-RPD and healthy control groups. Serum-tau would be a simple and useful marker to distinguish CJD from AD and non-CJD-RPD, requiring further large study to confirm this.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360196     DOI: 10.1007/s00415-011-5960-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  How to improve the clinical diagnosis of Creutzfeldt-Jakob disease.

Authors:  S Poser; B Mollenhauer; A Kraubeta; I Zerr; B J Steinhoff; A Schroeter; M Finkenstaedt; W J Schulz-Schaeffer; H A Kretzschmar; K Felgenhauer
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

2.  Dynamics of brain-derived proteins in cerebrospinal fluid.

Authors:  H Reiber
Journal:  Clin Chim Acta       Date:  2001-08-20       Impact factor: 3.786

3.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

4.  Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease.

Authors:  H J Tschampa; M Neumann; I Zerr; K Henkel; A Schröter; W J Schulz-Schaeffer; B J Steinhoff; H A Kretzschmar; S Poser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-07       Impact factor: 10.154

5.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

6.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

7.  Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke.

Authors:  Michael T Wunderlich; Hartmut Lins; Martin Skalej; Claus-W Wallesch; Michael Goertler
Journal:  Clin Neurol Neurosurg       Date:  2006-02-02       Impact factor: 1.876

8.  Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

Authors:  E Kapaki; K Kilidireas; G P Paraskevas; M Michalopoulou; E Patsouris
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

9.  Prospective 10-year surveillance of human prion diseases in Japan.

Authors:  Ichiro Nozaki; Tsuyoshi Hamaguchi; Nobuo Sanjo; Moeko Noguchi-Shinohara; Kenji Sakai; Yosikazu Nakamura; Takeshi Sato; Tetsuyuki Kitamoto; Hidehiro Mizusawa; Fumio Moriwaka; Yusei Shiga; Yoshiyuki Kuroiwa; Masatoyo Nishizawa; Shigeki Kuzuhara; Takashi Inuzuka; Masatoshi Takeda; Shigetoshi Kuroda; Koji Abe; Hiroyuki Murai; Shigeo Murayama; Jun Tateishi; Ichiro Takumi; Susumu Shirabe; Masafumi Harada; Atsuko Sadakane; Masahito Yamada
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

10.  Medical procedures and risk for sporadic Creutzfeldt-Jakob disease, Japan, 1999-2008.

Authors:  Tsuyoshi Hamaguchi; Moeko Noguchi-Shinohara; Ichiro Nozaki; Yosikazu Nakamura; Takeshi Sato; Tetsuyuki Kitamoto; Hidehiro Mizusawa; Masahito Yamada
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

View more
  17 in total

1.  Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease.

Authors:  Ming-Jang Chiu; Ya-Fang Chen; Ta-Fu Chen; Shieh-Yueh Yang; Fan-Pei Gloria Yang; Tien-Wen Tseng; Jen-Jie Chieh; Jia-Chun Rare Chen; Kai-Yuan Tzen; Mau-Sun Hua; Herng-Er Horng
Journal:  Hum Brain Mapp       Date:  2013-10-15       Impact factor: 5.038

2.  CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result.

Authors:  M J Leitão; I Baldeiras; M R Almeida; M H Ribeiro; A C Santos; M Ribeiro; J Tomás; S Rocha; I Santana; C R Oliveira
Journal:  J Neurol       Date:  2016-06-29       Impact factor: 4.849

Review 3.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

4.  Tau is reduced in AD plasma and validation of employed ELISA methods.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Chuck Ziolkowski; Yushun Lin; Lisa M Sparks; Carolyn Liebsack; Sherry Johnson-Traver
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

5.  Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.

Authors:  Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova
Journal:  Mol Neurobiol       Date:  2016-09-24       Impact factor: 5.590

6.  Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Authors:  C Vergara; L Ordóñez-Gutiérrez; F Wandosell; I Ferrer; J A del Río; R Gavín
Journal:  Mol Neurobiol       Date:  2014-06-26       Impact factor: 5.590

Review 7.  Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.

Authors:  Peter Hermann; Brian Appleby; Jean-Philippe Brandel; Byron Caughey; Steven Collins; Michael D Geschwind; Alison Green; Stephane Haïk; Gabor G Kovacs; Anna Ladogana; Franc Llorens; Simon Mead; Noriyuki Nishida; Suvankar Pal; Piero Parchi; Maurizio Pocchiari; Katsuya Satoh; Gianluigi Zanusso; Inga Zerr
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

8.  Will posttranslational modifications of brain proteins provide novel serological markers for dementias?

Authors:  Y Wang; M G Sørensen; Q Zheng; C Zhang; M A Karsdal; K Henriksen
Journal:  Int J Alzheimers Dis       Date:  2012-06-21

9.  The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation.

Authors:  Dora Brites
Journal:  Front Pharmacol       Date:  2012-05-29       Impact factor: 5.810

Review 10.  Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.

Authors:  Aaron Ritter; Jeffrey Cummings
Journal:  Front Neurol       Date:  2015-08-31       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.